CLYMClimb Bio, Inc.

$522M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$56M

Net Income

-$55M

EPS (Diluted)

$-1.81

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$667,000

Free Cash Flow

-$667,000

Stock-Based Comp.

$512,000

Balance Sheet

Total Assets

$226M

Total Liabilities

$4M

Stockholders' Equity

$222M

Cash & Equivalents

$223M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$56M	-$7M	-739.6%
Net Income	-$55M	-$5M	-951.5%

CLYM Q2 2024 Earnings — Climb Bio, Inc. Revenue & Financial Results | Market Cap Arena